{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T11:03:03Z","timestamp":1760266983661},"reference-count":23,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2009,9,29]],"date-time":"2009-09-29T00:00:00Z","timestamp":1254182400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatism"],"published-print":{"date-parts":[[2009,10,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>To assess L\u2010tryptophan (LT) dose, age, sex, and immunogenetic markers as possible risk or protective factors for the development of LT\u2010associated eosinophilia\u2013myalgia syndrome (EMS) and related clinical findings.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>HLA\u2013DRB1 and DQA1 allele typing and Gm\/Km phenotyping were performed on a cohort of 94 white subjects with documented LT ingestion and standardized evaluations. Multivariate analyses compared LT dose, age, sex, and alleles among groups of subjects who ingested LT and subsequently developed surveillance criteria for EMS, developed EMS or characteristic features of EMS (EMS spectrum disorder), or developed no features of EMS (unaffected).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Considering all sources of LT, higher LT dose (odds ratio [OR] 1.4, 95% confidence interval [95% CI] 1.1\u20131.8), age &gt;45 years (OR 3.0, 95% CI 1.0\u20138.8), and HLA\u2013DRB1*03 (OR 3.9, 95% CI 1.2\u201315.2), DRB1*04 (OR 3.9, 95% CI 1.1\u201316.4), and DQA1*0601 (OR 13.7, 95% CI 1.3\u20131.8) were risk factors for the development of EMS, whereas DRB1*07 (OR 0.12, 95% CI 0.02\u20130.48) and DQA1*0501 (OR 0.23, 95% CI 0.05\u20130.85) were protective. Similar risk and protective factors were seen for developing EMS following ingestion of implicated LT, except that DRB1*03 was not a risk factor and DQA1*0201 was an additional protective factor. EMS spectrum disorder also showed similar findings, but with DRB1*04 being a risk factor and DRB1*07 and DQA1*0201 being protective. There were no differences in sex distribution, Gm\/Km allotypes, or Gm\/Km phenotypes among any groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In addition to the xenobiotic dose and subject age, polymorphisms in immune response genes may underlie the development of certain xenobiotic\u2010induced immune\u2010mediated disorders, and these findings may have implications for future related epidemics.<\/jats:p><\/jats:sec>","DOI":"10.1002\/art.24460","type":"journal-article","created":{"date-parts":[[2009,9,29]],"date-time":"2009-09-29T10:28:11Z","timestamp":1254220091000},"page":"1305-1311","source":"Crossref","is-referenced-by-count":16,"title":["Immunogenetic risk and protective factors for the development of L\u2010tryptophan\u2013associated eosinophilia\u2013myalgia syndrome and associated symptoms"],"prefix":"10.1002","volume":"61","author":[{"given":"Satoshi","family":"Okada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary L.","family":"Kamb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janardan P.","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rossanne M.","family":"Philen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lori A.","family":"Love","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederick W.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,9,29]]},"reference":[{"key":"e_1_2_7_2_2","first-page":"2","article-title":"The eosinophilia\u2010myalgia syndrome: what we know, what we think we know, and what we need to know","volume":"46","author":"Clauw DJ","year":"1996","journal-title":"J Rheumatol Suppl"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199008093230601"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1992.03480010085029"},{"key":"e_1_2_7_5_2","first-page":"666","article-title":"Risk factors for developing eosinophilia myalgia syndrome among L\u2010tryptophan users in New York","volume":"20","author":"Back EE","year":"1993","journal-title":"J Rheumatol"},{"key":"e_1_2_7_6_2","first-page":"60","article-title":"Bias or biology: evaluating the epidemiologic studies of L\u2010tryptophan and the eosinophilia\u2010myalgia syndrome","volume":"46","author":"Horwitz RI","year":"1996","journal-title":"J Rheumatol Suppl"},{"key":"e_1_2_7_7_2","first-page":"44","article-title":"Epidemiologic studies of the association of L\u2010tryptophan with the eosinophilia\u2010myalgia syndrome: a critique","volume":"46","author":"Shapiro S","year":"1996","journal-title":"J Rheumatol Suppl"},{"key":"e_1_2_7_8_2","first-page":"2385","article-title":"Eosinophilia\u2010myalgia syndrome not associated with the ingestion of nutritional supplements","volume":"21","author":"Clauw DJ","year":"1994","journal-title":"J Rheumatol"},{"key":"e_1_2_7_9_2","first-page":"1784","article-title":"Eosinophilia\u2010myalgia syndrome among the non\u2010L\u2010tryptophan users and pre\u2010epidemic cases","volume":"23","author":"Sullivan EA","year":"1996","journal-title":"J Rheumatol"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)91717-9"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1994.154"},{"key":"e_1_2_7_12_2","doi-asserted-by":"crossref","first-page":"249","DOI":"10.4049\/jimmunol.148.1.249","article-title":"Polymorphism, recombination, and linkage disequilibrium within the HLA class II region","volume":"148","author":"Begovich AB","year":"1992","journal-title":"J Immunol"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10358"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2007.12.003"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.2687"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1177\/0962280207084156"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-116-2-140"},{"key":"e_1_2_7_18_2","first-page":"19","article-title":"Eosinophilia\u2010myalgia syndrome: patient status 2\u20104 years after onset","volume":"46","author":"Pincus T","year":"1996","journal-title":"J Rheumatol Suppl"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199803)41:3<400::AID-ART4>3.0.CO;2-5"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2005.09.008"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1568-9972(01)00004-0"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.2001.01559.x"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0300-483X(96)03584-6"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1744-313X.1996.tb00116.x"}],"container-title":["Arthritis Care &amp; Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.24460","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.24460","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T17:15:00Z","timestamp":1697130900000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/art.24460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9,29]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2009,10,15]]}},"alternative-id":["10.1002\/art.24460"],"URL":"https:\/\/doi.org\/10.1002\/art.24460","archive":["Portico"],"relation":{},"ISSN":["0893-7524","1529-0123"],"issn-type":[{"value":"0893-7524","type":"print"},{"value":"1529-0123","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9,29]]}}}